11 – 20 of 22
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Pharmaceutical industry payments to NHS trusts in England : A four-year analysis of the Disclosure UK database
- Contribution to journal › Article
-
Mark
Authors’ reply to Fell
- Contribution to journal › Letter
- 2022
-
Mark
Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
- Contribution to journal › Article
-
Mark
Content and strength of conflict of interest policies at Scandinavian Medical Schools: a cross sectional study
- Contribution to journal › Article
-
Mark
Capitalizing on transparency: commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
- Contribution to journal › Article
-
Mark
A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
- Contribution to journal › Article
-
Mark
Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
- Contribution to journal › Article
-
Mark
Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
- Contribution to journal › Article
- 2021
-
Mark
Pharmaceutical industry self-regulation and non-transparency : country and company level analysis of payments to healthcare professionals in seven European countries
- Contribution to journal › Article
-
Mark
Drug company payments to General Practices in England: cross-sectional and social network analysis
- Contribution to journal › Article